lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
==== Pharmacokinetics ==== Dronabinol reaches its highest concentration in blood within 1–2 hours of administration. Food intake increases the time and extent of drug absorption, causing a higher drug concentration in blood at a later time. The high lipid solubility of Dronabinol causes its accumulation in fatty organs such as the heart, liver and spleen. Dronabinol is mostly metabolized by CYP2C9 (an enzyme majorly found in the liver) into 11-hydroxy-delta-9-THC, an active molecule that can enter the brain and cause depression or anxiety. More side effects may be seen in patients with diminished CYP2C9 enzyme activity due to the reduced dronabinol metabolism. Dronabinol is majorly eliminated from the body with faeces.
=== January === 1 January Helen Hogan, educator (Hillmorton High School, WEA), editor of poetry anthologies, and Māori studies scholar (born 1923). Lyn Fleming, Police senior sergeant and first policewoman in New Zealand to be killed in the line of duty (born 1963). 2 January – Lex Clark, Olympic rower (1964) (born 1943). 3 January Kate Coolahan, commercial artist, fashion illustrator, printmaker, and design educator (Wellington Polytechnic) (born 1929). Dame Tariana Turia, politician, Labour list MP (1996–2002), MP for Te Tai Hauāuru (2002–2014), co-leader of the Māori Party (2004–2014), Minister for the Community and Voluntary Sector (2003–2004, 2008–2011), Minister for Disability Issues (2009–2014), Minister for Whānau Ora (2010–2014) (born 1944). 5 January Philippa Blair, artist (born 1945). Lou Robinson, structural engineer and heritage advocate (born 1943). 7 January – Arthur Pomeroy, classical scholar (Victoria University of Wellington), chess player and administrator (born 1953). 18 January – Russell Marshall, politician and diplomat, MP for Wanganui (1972–1990), Minister of Education (1984–1987), Minister of Foreign Affairs (1987–1990), chancellor of Victoria University of Wellington (2000–2002), High Commissioner to the United Kingdom (2002–2005) (born 1936). 19 January – David Johnston, disaster researcher (Massey University) (born 1966). 20 January – Richard Hipa, Niuean public servant and politician, Secretary of Government (2008–2017), Member of the Niue Assembly (2020–2023) (born 1957). 21 January Diana Beaglehole, historian (born 1938).
Includes the perirhinal and entorhinal cortices. Rhombencephalon Also known as the hindbrain, this embryonic brain region gives rise to the pons, medulla oblongata, and cerebellum. Ribosome A cellular organelle responsible for protein synthesis. In neurons, local ribosome activity occurs in dendrites and axons, supporting synaptic plasticity. Rostral A directional term meaning “toward the nose” or front of the brain. Often used in anatomical descriptions of the central nervous system. Ruffini ending A slow-adapting mechanoreceptor found in the skin that detects skin stretch and contributes to proprioception and object manipulation. RUNX1 A transcription factor involved in sensory neuron differentiation and pain signaling. Active during embryonic development and in peripheral nervous system patterning.
Sources: en.wikipedia.org
==== Maintenance phase ==== After the 5–7 day loading phase, muscle creatine stores are fully saturated and supplementation only needs to cover the amount of creatine broken down per day. This maintenance dose was originally reported to be around 2–3 g/day (or 0.03 g/kg/day), however, some studies have suggested 3–5 g/day maintenance dose to maintain saturated muscle creatine.
If you can watch that back and call that serious, then (looking at the promoter) you're f...d, and KSW is going down the f...g toilet." Two days later the promotion changed the result to a No Contest. During a conference held on 28 November, the ruling was deemed to be a "judge's error" and the fight result was changed. Mariusz's next opponent was Bob Sapp in a fight took place in Łódź, Poland on KSW 19 on 12 May 2012. Mariusz won via a TKO in the first round, battering Sapp with a barrage of punching and securing a takedown followed with more punches to win just 39 seconds into the fight. Mariusz then faced Christos Piliafas on 15 September in the main event of KSW 20. Mariusz won via TKO in the first round, after dominating Piliafas on his feet, he then secured a takedown followed by posturing up and raining down some ground and pound to win at 3:48 seconds into the fight. On 8 June 2013, Pudzianowski fought Sean McCorkle at KSW 23, losing the bout in the first round by kimura submission. Pudzianowski fought McCorkle again in a rematch on 28 September at KSW 24, avenging his loss via unanimous decision. After the second fight, Sean McCorkle expressed interest in a third fight. On 17 May 2014 at KSW 27, Pudzianowski defeated Oli Thompson via a 2nd round unanimous decision. During the fight, Pudzianowski was able to gain points by controlling the entire fight through landing punches and securing multiple takedowns in both rounds eventually leading to his victory. At the end, Thompson requested a rematch, to which Pudzianowski agreed.
Bioadhesives inspired by gastropods are biomimetic adhesive materials modeled on the mucus of gastropods such as snails and slugs. Gastropod mucus is a viscoelastic secretion containing glycoproteins, glycosaminoglycans, enzymes, and metal ions, and can adhere to wet surfaces. Gastropod-inspired adhesives reproduce aspects of this adhesion through chemical bonding, mechanical interlocking, electrostatic interactions, and cross-linking. Energy-dissipating polymer networks can contribute to their mechanical strength and toughness. Research on gastropod-inspired bioadhesives has focused particularly on biomedical applications, including wound closure, tissue sealing, drug delivery, dental applications, and the attachment of medical devices. Experimental systems include hydrogel adhesives designed to maintain adhesion to wet and moving biological tissues, and some have also been studied for antimicrobial activity and biocompatibility.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.